

Cover Story
FreeNews Analysis
By Matthew Bin Han Ong
Now that Joseph R. Biden Jr. is inaugurated and safely ensconced in the White House, cancer groups expect him to pick up where he left off as vice president four years ago—pursuing a sober and ambitious agenda for accelerating progress in cancer research.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure
- The Directors: Ruben Mesa and Kunle Odunsi on how immigration and diversity accelerate discovery
“This has always made our environment stronger, not weaker.” - HHS (again) postpones USPSTF meeting














